CJC-1295 + Ipamorelin 10mg/mL

Route: Subcutaneous injection as prescribed.

• Inject subcutaneously into the abdomen, thigh, or upper arm; rotate injection sites to prevent lipohypertrophy.
• Use strict aseptic technique: cleanse the site with an alcohol swab, allow to dry, and inject with a new sterile needle and syringe.
• Do not administer intravenously unless specifically directed by the prescriber.
• For nighttime dosing (preferred): administer 30–60 minutes before sleep, on an empty stomach (at least 2 hours after eating) to align with the physiological nocturnal GH pulse and avoid somatostatin interference from high insulin states.

There are no FDA-approved dosing guidelines. Dosing is entirely prescriber-determined based on available clinical research and patient-specific goals:

• The prescriber specifies the dose volume (mg or mcg) and frequency (commonly 5 days/week or daily, subcutaneously).
• Human research with CJC-1295 has studied doses of 30–90 mcg/kg; ipamorelin human trial doses have varied by study. The prescriber integrates these data with clinical judgment.
• Cycling protocols are common; typical approaches include 3 months on, 1 month off to prevent receptor desensitization.

• CJC-1295: Synthetic analog of GHRH(1-29) modified with a drug affinity complex (DAC) that reversibly binds albumin, dramatically extending half-life to ~6–8 days in humans. Binds GHRH receptors on pituitary somatotrophs, stimulating GH synthesis and release; results in sustained elevation of circulating GH and downstream IGF-1 over days following a single injection.
• Ipamorelin: Pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that binds the ghrelin receptor (GHSR-1a) on pituitary somatotrophs; stimulates a rapid, pulsatile release of GH with high receptor selectivity—importantly, ipamorelin does not significantly elevate ACTH, cortisol, FSH, LH, prolactin, or TSH at pharmacologically active doses, distinguishing it from other GHRPs. The combination provides both a sustained GH baseline (CJC-1295) and a pulsatile GH peak (ipamorelin), mimicking physiologic GH secretion patterns more closely than either agent alone.

CJC-1295 and ipamorelin are used prescriber-directed for adult patients with growth hormone deficiency or age-related decline in GH/IGF-1 axis function in whom stimulation of endogenous GH is preferable to exogenous rhGH replacement. The combination approach targets pituitary reserve rather than bypassing it, and the selective profile of ipamorelin minimizes off-target endocrine effects.

Prescriber monitoring:

• Baseline and periodic: serum IGF-1 levels (primary efficacy marker), fasting glucose (GH can cause insulin resistance), fasting insulin.
• Monitor for fluid retention (edema), carpal tunnel syndrome, and arthralgias—common with elevated GH states.
• Contraindicated in active malignancy; GH promotes cellular proliferation.
• Monitor for injection site reactions; rotate sites consistently.

Contraindications:

• Active malignancy or history of cancer (growth-promoting effects of elevated GH/IGF-1)
• Known hypersensitivity to either peptide or formulation excipients
• Severe pituitary disease with absent secretory reserve (peptide stimulation requires functional pituitary)

Warnings & Precautions:

• CJC-1295 and ipamorelin are not FDA-approved; long-term safety and efficacy data in humans are limited.
• CJC-1295 may cause transient cardiovascular effects including flushing, warmth, and transient hypotension; the FDA has issued a safety concern regarding increased heart rate and systemic vasodilation.
• Elevated IGF-1 levels have theoretical associations with increased cancer risk in long-term use; this is not established for short-course use at physiologic doses.
• Insulin resistance may develop with supraphysiologic GH elevation; monitor fasting glucose.
• Prescribers must ensure informed consent documenting the investigational nature of this therapy.

Drug Interactions:

• Insulin and hypoglycemic agents: elevated GH antagonizes insulin action; dose adjustment may be needed.
• Glucocorticoids may blunt GH response to secretagogue stimulation.
• Thyroid hormones: GH stimulates T4-to-T3 conversion; monitor thyroid function in patients on thyroid replacement.

Common Side Effects: Injection site reactions (erythema, pain, bruising); transient flushing, warmth, or headache post-injection; water retention, peripheral edema; arthralgias; potential for morning headache if IGF-1 rises rapidly.

Store refrigerated at 2–8°C (36–46°F). Protect from light. Do not freeze. CJC-1295 and ipamorelin are peptides sensitive to heat, light, and freeze-thaw cycles. Bring to room temperature before injection. Use before the beyond-use date assigned by Genesis Compounding. Keep out of reach of children.

Why combine CJC-1295 and ipamorelin?

CJC-1295 provides sustained baseline elevation of growth hormone through a prolonged GHRH-receptor signal, while ipamorelin induces a more immediate, pulsatile GH release via the ghrelin receptor. Together, they produce a more physiologic GH secretion pattern—both a sustained background and distinct peaks—than either agent alone, and their complementary mechanisms provide synergistic GH stimulation.

Is ipamorelin selective for GH, or does it affect other hormones?

Ipamorelin is the first characterized selective GHRP-receptor agonist for GH release. Unlike older GHRPs (GHRP-2, GHRP-6), ipamorelin does not significantly elevate ACTH, cortisol, FSH, LH, prolactin, or TSH at pharmacologically active doses, making it the most hormone-selective GHRP available.

Are CJC-1295 and ipamorelin FDA-approved?

No. Neither peptide is FDA-approved for any indication. This is a 503A compounded sterile preparation from Genesis Compounding for a specific patient per a prescriber's order. The use is investigational and prescribers must ensure patients are fully informed.

When should I inject this medication?

Evening or bedtime injection is generally preferred to align with the body's natural nocturnal GH surge. Inject on an empty stomach (at least 2 hours after the last meal) to minimize somatostatin inhibition from elevated insulin levels that would blunt the GH response.

How should I store the vials?

Refrigerate at 2–8°C (36–46°F). Protect from light. Never freeze. Bring to room temperature before injection. Use within the beyond-use date labeled by Genesis Compounding.